

www.tajpharma.com

Give with food. Swallow tablets whole; use only intact tablets.

- Starting dose: 0.25 mg BID.

- Titrate by 0.25 mg or 0.5 mg BID or 0.125 mg TID, not more than every 3 to 4 days as tolerated.

- Maximum dose is determined by tolerability.

- Mild hepatic impairment (Child Pugh Class A): Initiate at 0.125 mg BID. Increment at 0.125 mg BID every 3 to 4 days.

- Avoid use in patients with moderate hepatic impairment.

  
**Xretten™**  
(treprostinil)  
Extended-Release Tablets

Treatment for: Pulmonary Hypertension  
Xretten™ (treprostinil extended-release)  
is an oral prostacyclin for the treatment  
of pulmonary arterial hypertension.



  
**Xretten™**  
(treprostinil)  
Extended-Release Tablets

Xretten™ is a prescription medicine used to treat pulmonary arterial hypertension (PAH) which is high blood pressure in the arteries of your lungs. Xretten™ may improve your ability to exercise. It is not known if Xretten™ is safe and effective in children under 18 years of age.

What is Xretten™?

Xretten™ is a prostacyclin class therapy available by prescription only. It is approved for the treatment of PAH to improve exercise ability. It is not known if Xretten™ is safe and effective in children under 18 years of age.

If you have PAH, talking to your healthcare provider can help determine if treatment with Xretten™ may be right for you.

Xretten™ may improve your ability to exercise

In a clinical study of PAH patients with functional class II-III symptoms, patients taking Xretten™ were able to walk farther than those taking placebo (sugar pill). For you, that may mean you see a positive difference in your ability to perform physical activities, such as walking.

**Xretten™ is a prostacyclin vasodilator indicated for:**

- Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. The study that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (75%) or PAH associated with connective tissue disease (19%).

As the sole vasodilator, the effect on exercise is small. Xretten™ has not been shown to add to other vasodilator therapy.

**Xretten™ (treprostinil) Extended-Release Tablets:** 0.125 mg, 0.25 mg, 1 mg and 2.5 mg.

**Treatment for:** Pulmonary Hypertension

Xretten™ (treprostinil extended-release) is an oral prostacyclin for the treatment of pulmonary arterial hypertension.

**Food and Drug Administration (FDA) approved .Prescription Only (POM)**

  
**Xretten™**  
(treprostinil)  
Extended-Release Tablets

A Taj Pharma™ India Product